Laura Joszt, MA

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.

The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.

Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.

Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.

Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.

A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.

Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.

Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.

Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.

Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.

Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

J&J's Oncology Care Index finds a systems problem, not a confidence gap, in community oncology, Mahadi Baig, MD, says.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable

FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.

Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD, explained.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

Lung transplant candidates are aging rapidly, while cystic fibrosis decline in children shifts pediatric transplant toward sicker, more complex patients.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

Exposure prevention, primary care capacity, and digital health equity all shape the future of respiratory disease care.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.

COPD kills at rates rivaling heart failure and exceeding prostate and breast cancer, per a new study and US mortality data.

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Poor cardiovascular health, especially high BMI and poor sleep, is linked to a substantially higher risk of overactive bladder, new data show.